Physician profile
Douglas Gregory Tacket
NPI 1790764868
$3,197.89
in general payments reported to CMS, 2019-2025
31 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,179 · 2020: $479 · 2021: $309 · 2022: $371 · 2023: $410 · 2024: $171 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $859.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $519.74 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astellas Pharma US INC | $323.97 | 2019-2023 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $295.24 | 2019-2023 | |
| Amgen INC. | $294.27 | 2019-2025 | Evenity |
| Janssen Pharmaceuticals, INC | $261.16 | 2019-2021 | |
| Lilly USA, LLC | $206.27 | 2019-2025 | Mounjaro, Zepbound |
| Allergan, INC. | $179.41 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $174.09 | 2019-2024 | Farxiga |
| Abbvie INC. | $155.41 | 2021-2025 | |
| Esperion Therapeutics, INC. | $125.00 | 2020 | |
| Pfizer INC. | $96.42 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.82 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $59.57 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Glaxosmithkline, LLC. | $55.28 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $46.44 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $40.76 | 2022-2023 | Unithroid |
| Dexcom, INC. | $37.24 | 2021-2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $32.91 | 2019-2020 | |
| Sanofi Pasteur INC. | $28.58 | 2022 | |
| Abbott Laboratories | $23.43 | 2022 | |
| Lundbeck LLC | $21.13 | 2025 | Rexulti |
| Paratek Pharmaceuticals, INC. | $18.07 | 2021 | |
| Axsome Therapeutics, INC. | $17.91 | 2025 | Auvelity |
| Shire North American Group INC | $17.53 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.51 | 2023 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $17.25 | 2019 | |
| Insulet Corporation | $15.81 | 2022 | |
| Eisai INC. | $15.78 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.16 | 2022 | |
| Xeris Pharmaceuticals, INC. | $14.49 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Tacket listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.